Alvarez, X. A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., Doppler, E., Moessler, H.

Background: Cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14–20) included in a dose‐finding study (ITT data set: N = 251; MMSE: 14–25). Results of the […]

Alvarez, X. Anton, Cacabelos, R., Sampedro, C., Couceiro, V., Aleixandre, M., Vargas, M., Linares, C., Granizo, E., García-Fantini, M., Baurecht, W., Doppler, E., Moessler, H.

Treatment with neurotrophic agents might enhance and/or prolong the effects of cholinesterase inhibitors (ChEIs) in Alzheimer’s disease (AD). We compared the safety and efficacy of the neurotrophic compound Cerebrolysin (10 ml; n=64), donepezil (10 mg; n=66) and a combination of both treatments (n=67) in mild-to-moderate (mini-mental state examination-MMSE score 12-25) probable AD patients enrolled in […]

Alvarez, X. A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., Doppler, E., Moessler, H.

Background: cerebrolysin is a neuropeptide preparation mimicking the effects of neurotrophic factors. This subgroup analysis assessed safety and efficacy of Cerebrolysin in patients with moderate to moderately severe Alzheimer’s disease (AD) (ITT data set: N = 133; MMSE: 14-20) included in a dose-finding study (ITT data set: N = 51; MMSE: 14-25). Results of the […]

Muresanu, Dafin F., Alvarez, X. Anton, Moessler, Herbert, Novak, Philipp H., Stan, Adina, Buzoianu, Anca, Bajenaru, Ovidiu, Popescu, Bogdan O.

The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]

Alvarez, X. Anton, Sampedro, Carolina, Cacabelos, Ramon, Linares, Carlos, Aleixandre, Manuel, García-Fantini, Manuel, Moessler, Herbert

According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]